Phase I experience with rogaratinib in patients (pts) with urothelial carcinoma (UC) selected based on FGFR mRNA overexpression.

Emmanuelle Kempf,Nicolas Penel,Christophe Tournigand,Pablo Gajate,Daniel Shao-Weng Tan,Philippe Cassier,Lucia Nogova,Richard Cathomas,Martin Schostak,A. Janitzky,Martin Wermke,Cyrus Sayehli,Alejandro Navarro,Se Hoon Park,Ana-Maria Piciu,Sebastian Bender,Hendrik Nogai,Peter Ellinghaus,Markus Joerger,Martin Schuler

Phase I experience with rogaratinib in patients (pts) with urothelial carcinoma (UC) selected based on FGFR mRNA overexpression.

2020

527Background: Aberrant activation of the fibroblast growth factor receptor (FGFR) pathway is implicated in many cancers, including UC. In a recent Phase I dose-escalation study, rogaratinib, an or...

Keywords:

Cancer research
Messenger RNA
Pathology
Fibroblast growth factor receptor
Carcinoma
Medicine
urothelial carcinoma
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations